(lp0
S"Aviragen Therapeutics Inc : What's Next? Insider Financial - Feb 16, 2017 Aviragen Therapeutics Inc  is not having a good week. The company just put out data from a phase 2 study of its lead development asset, and has taken a close to 40% hit on the news.Aviragen Therapeutics Announces Top-Line Results From Phase 2b SPIRITUS Trial ... - Clinical Leader"
p1
aS"Aviragen Therapeutics slammed again by its second trial failure in days, this ... Endpoints News - Feb 13, 2017 In back-to-back setbacks, Aviragen Therapeutics $AVIR says that its lead drug vapendavir flunked a Phase IIb in moderate to severe asthmatics with a rhinovirus infection.Aviragen Therapeutics'  Phase 2b SPIRITUS Trial of Vapendavir Fails - StreetInsider.com"
p2
aS'Biota Pharmaceuticals Is Now Aviragen Therapeutics Seeking Alpha - Apr 27, 2016 Subsequent to our last update on Aviragen Therapeutics, the company has been busy attending and presenting at industry conferences.'
p3
aS"Aviragen Therapeutics'  CEO Joseph Patti on Q2 2017 Results - Earnings ... Seeking Alpha - Feb 3, 2017 Good day, ladies and gentlemen, and welcome to the Aviragen Therapeutics, Inc. Second Quarter 2017 Financial Results Conference Call.Aviragen Hits 52-Week Low on Drug Failure  - Investopedia"
p4
aS'Aviragen Therapeutics Inc. MarketWatch - May 4, 2016 Aviragen Therapeutics Inc. NASDAQ: AVIR. GO. Set Alerts &middot; Find a Broker &middot; Join TD Ameritrade &middot; Market Index &middot; Overview Profile News Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders.'
p5
aS'Aviragen Therapeutics Completes Royalty Deal With HealthCare Royalty Partners ... GlobeNewswire  - Apr 25, 2016 ATLANTA, April 25, 2016  -- Aviragen Therapeutics, Inc.   a pharmaceutical company that is developing the next generation of antivirals, today announced that it has signed a&nbsp;...'
p6
aS'BRIEF-Aviragen Therapeutics announces top-line results from phase 2b SPIRITUS ... Reuters - Feb 13, 2017 Feb 13 Aviragen Therapeutics Inc. * Aviragen Therapeutics announces top-line results from phase 2b SPIRITUS trial of Vapendavir.'
p7
aS'Analyst Advice And Earnings Insight: Aviragen Therapeutics, Inc. (AVIR ... Post Analyst - 23 hours ago Aviragen Therapeutics, Inc.  surprised the stock market in its last reported earnings when it earned -$0.24 a piece versus the consensus-estimated -$0.26.'
p8
aS"Biota Pharma  Becomes Aviragen Therapeutics; Will Trade Under 'AVIR' StreetInsider.com - Apr 12, 2016 Biota Pharmaceuticals, Inc.  announced that the Company has changed its name to Aviragen Therapeutics, Inc., , a pharmaceutical company focused on the development of the next generation of direct-acting&nbsp;..."
p9
aS"Mid-Day Market Update: RetailMeNot Gains After Strong Q4 Results; Aviragen ... Nasdaq - Feb 14, 2017 Aviragen Therapeutics Inc  shares dropped 37 percent to $0.681 after the company reported top-line results from its Phase 2b SPIRITUS trial of vapendavir.4 Stocks That Are Breaking Hearts on Valentine's Day - 24/7 Wall St."
p10
a.